Anna Protopapas - Mersana Therapeutics President CEO, Director
| MRSN Stock | USD 3.17 0.01 0.32% |
CEO
Ms. Anna Protopapas is the President, Chief Executive Officer, Director of the Company. She bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms. Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.s 1.3 billion oncology business. Ms. Protopapas also served as the Executive Vice President of Global Business Development for Takeda Pharmaceuticals where she was responsible for global acquisitions, partnering, licensing and venture investing. In this role, she led Takedas 12 billion acquisition of Nycomed, a critical step in the companys globalization. Ms. Protopapas was a member of Takedas executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the companys transformation from a genomics startup to a fully integrated oncology leader. She was instrumental in the sale of Millennium to Takeda for 8.8 billion since 2016.
| Age | 53 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 840 Memorial Drive, Cambridge, MA, United States, 02139 |
| Phone | 617 498 0020 |
| Web | https://www.mersana.com |
Anna Protopapas Latest Insider Activity
Tracking and analyzing the buying and selling activities of Anna Protopapas against Mersana Therapeutics stock is an integral part of due diligence when investing in Mersana Therapeutics. Anna Protopapas insider activity provides valuable insight into whether Mersana Therapeutics is net buyers or sellers over its current business cycle. Note, Mersana Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mersana Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Anna Protopapas over a month ago Acquisition by Anna Protopapas of 16750 shares of Mersana Therapeutics subject to Rule 16b-3 | ||
Anna Protopapas over three months ago Exercise or conversion by Anna Protopapas of 31250 shares of Mersana Therapeutics subject to Rule 16b-3 | ||
Anna Protopapas over six months ago Acquisition by Anna Protopapas of 16643 shares of Mersana Therapeutics subject to Rule 16b-3 |
Mersana Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3813) % which means that it has lost $0.3813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6624) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of May 2024, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to drop to -1.11. At this time, Mersana Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 1st of May 2024, Asset Turnover is likely to grow to 0.23, while Total Assets are likely to drop about 180.4 M.Similar Executives
| Found 14 records | CEO Age | ||
| Robert Coffin | Replimune Group | 59 | |
| Ton Logtenberg | Merus BV | N/A | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Richard Hamilton | Cerevel Therapeutics Holdings | 51 | |
| Daniel MBA | Acumen Pharmaceuticals | 53 | |
| Briggs Morrison | Syndax Pharmaceuticals | 56 | |
| Arlene Morris | Syndax Pharmaceuticals | 63 | |
| MBA JD | Viridian Therapeutics | 54 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| MBA Renaud | Cerevel Therapeutics Holdings | 55 | |
| Nadim Ahmed | Cullinan Oncology LLC | 56 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Dinesh Patel | Protagonist Therapeutics | 67 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 |
Mersana Therapeutics Leadership Team
Elected by the shareholders, the Mersana Therapeutics' board of directors comprises two types of representatives: Mersana Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mersana. The board's role is to monitor Mersana Therapeutics' management team and ensure that shareholders' interests are well served. Mersana Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mersana Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Damelin, Oncology, Biology | ||
| Ashish Mandelia, Vice President Controller | ||
| Mohan Bala, Senior Officer | ||
| Tushar Misra, Senior Officer | ||
| Eva Jack, Chief Business Officer | ||
| MD Huber, CEO President | ||
| Willard Dere, Independent Director | ||
| Michael Kaufman, Senior Vice President - Chemistry, Manufacturing and Controls | ||
| Andrew Hack, Independent Director | ||
| Wayne Foster, Vice President - Finance | ||
| Dirk Huebner, Chief Medical Officer | ||
| Anna MBA, CEO Pres | ||
| Brian DeSchuytner, Senior Vice President - Finance and Product Strategy | ||
| Chuck Miller, Senior Affairs | ||
| Carla Poulson, Chief Officer | ||
| Martin MD, CEO President | ||
| Jason Fredette, Senior Communications | ||
| David Spellman, CFO | ||
| Lawrence Alleva, Independent Director | ||
| Anna Protopapas, President CEO, Director | ||
| Timothy Lowinger, Chief Scientific Officer | ||
| Donald Bergstrom, Chief Medical Officer | ||
| Kristen Hege, Independent Director | ||
| Alejandra JD, Secretary SVP | ||
| David Mott, Chairman of the Board | ||
| Mikhail Papisov, CoFounder |
Mersana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mersana Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 208.06 M | ||||
| Shares Outstanding | 121.3 M | ||||
| Shares Owned By Insiders | 1.31 % | ||||
| Shares Owned By Institutions | 94.47 % | ||||
| Number Of Shares Shorted | 10.58 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 12.49 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Mersana Stock analysis
When running Mersana Therapeutics' price analysis, check to measure Mersana Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mersana Therapeutics is operating at the current time. Most of Mersana Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mersana Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mersana Therapeutics' price. Additionally, you may evaluate how the addition of Mersana Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Mersana Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.317 | Quarterly Revenue Growth (0.27) | Return On Assets (0.38) | Return On Equity (2.66) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.